Lantheus Medical acquires global rights to ex-Epix product
Diagnostic imaging firm Lantheus Medical Imaging Inc. has acquired global rights to Ablavar, a blood pool imaging agent used in patients with peripheral vascular disease. The product was formerly owned by now-bankrupt Epix Pharmaceuticals Inc., which sold its assets at auction .
Ablavar is the U.S. market name for gadofosveset trisodium, a contrast agent used in magnetic resonance angiography to evaluate aortoiliac occlusive disease in adults either known or suspected to have peripheral vascular disease.
Prior to today’s announcement , North Billerica-based Lantheus held exclusive rights to Ablavar in the U.S., Canada and Australia. Outside the U.S., it was previously marketed as Vasovist.
Epix announced in July 2009 that it would liquidate its assets, and in September, the company held an auction for its intellectual property assets associated with its PRX-08066 treatment for chronic pulmonary disease and pulmonary hypertension treatment.